Hepion Pharmaceuticals Director Stetz Buys $25,000 in Stock

Stetz, a director at Hepion Pharmaceuticals, purchased $25,000 worth of common stock in the company. This buy indicates insider confidence in Hepion's future prospects. Such transactions can influence market perceptions and potentially affect stock performance. Investors may view insider purchases as a positive sign regarding the company's direction and stability.